KEGG pathways | Genes | Gene number | p value |
CpG island | |||
Neuroactive ligand-receptor interaction | HCRTR1, SSTR2, ADRB2, ADRB1, ADORA2A, OXTR, UTS2R, LHB, VIPR2, GRID1 | 10 | 0.0028 |
Bladder cancer | CDKN1A, E2F3, FGFR3 | 3 | 0.0669 |
Pathways in cancer | WNT5A, FGF8, CDKN1A, E2F3, FGFR3, PPARG, PTCH1, TCF3 | 8 | 0.0776 |
Lysine degradation | ALDH1B1, TMLHE, NSD1 | 3 | 0.0839 |
Prostate cancer | CDKN1A, E2F3, RGD1566107, TCF3 | 4 | 0.0918 |
Promoter area | |||
Neuroactive ligand-receptor interaction | SSTR2, ADRB2, ADRB1, GRM2, HRH2, ADORA2A, AVPR1B, OXTR, NTSR1, VIPR2, GRID1 | 11 | 0.0109 |
Calcium signaling pathway | ADRB2, ADRB1, HRH2, ADORA2A, AVPR1BCACNA1I, OXTR, NTSR1 | 8 | 0.0338 |
ECM-receptor interaction | CD44, COL1A2, ITGA11, TNN, COL1A | 5 | 0.0393 |
MAPK signaling pathway | ACVR1B, FGFR3, PDGFB, MAPK13, RASGRP4, CACNA1I, PLA2G1B, HSPB1, RASA1 | 9 | 0.0647 |